344 related articles for article (PubMed ID: 16435128)
1. Tumor immune escape mechanisms: impact of the neuroendocrine system.
Lang K; Entschladen F; Weidt C; Zaenker KS
Cancer Immunol Immunother; 2006 Jul; 55(7):749-60. PubMed ID: 16435128
[TBL] [Abstract][Full Text] [Related]
2. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
Hess AD; Thoburn CJ
Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
[TBL] [Abstract][Full Text] [Related]
3. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
Rivoltini L; Carrabba M; Huber V; Castelli C; Novellino L; Dalerba P; Mortarini R; Arancia G; Anichini A; Fais S; Parmiani G
Immunol Rev; 2002 Oct; 188():97-113. PubMed ID: 12445284
[TBL] [Abstract][Full Text] [Related]
4. New aspects of natural-killer-cell surveillance and therapy of cancer.
Smyth MJ; Hayakawa Y; Takeda K; Yagita H
Nat Rev Cancer; 2002 Nov; 2(11):850-61. PubMed ID: 12415255
[No Abstract] [Full Text] [Related]
5. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
Khong HT; Restifo NP
Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive strategies that are mediated by tumor cells.
Rabinovich GA; Gabrilovich D; Sotomayor EM
Annu Rev Immunol; 2007; 25():267-96. PubMed ID: 17134371
[TBL] [Abstract][Full Text] [Related]
7. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
8. Absence of antitumor natural killer cell-mediated defense in the brain.
Yamasaki T
Surg Neurol; 2004 Mar; 61(3):227-8. PubMed ID: 14984990
[No Abstract] [Full Text] [Related]
9. Immunological and neuroendocrine modulation of fever in stress.
Roth J
Prog Brain Res; 1998; 115():177-92. PubMed ID: 9632936
[No Abstract] [Full Text] [Related]
10. Mechanism of immune escape of cancer and its regulation.
Morita R; Hirohashi Y; Torigoe T
Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
[No Abstract] [Full Text] [Related]
11. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Shklovskaya E; Rizos H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
[TBL] [Abstract][Full Text] [Related]
12. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.
Bidwell BN; Slaney CY; Withana NP; Forster S; Cao Y; Loi S; Andrews D; Mikeska T; Mangan NE; Samarajiwa SA; de Weerd NA; Gould J; Argani P; Möller A; Smyth MJ; Anderson RL; Hertzog PJ; Parker BS
Nat Med; 2012 Aug; 18(8):1224-31. PubMed ID: 22820642
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
[TBL] [Abstract][Full Text] [Related]
14. The Fas/Fas ligand system and cancer: immune privilege and apoptosis.
Abrahams VM; Kamsteeg M; Mor G
Mol Biotechnol; 2003 Sep; 25(1):19-30. PubMed ID: 13679631
[TBL] [Abstract][Full Text] [Related]
15. NK cells and cancer immunosurveillance.
Waldhauer I; Steinle A
Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
[TBL] [Abstract][Full Text] [Related]
16. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
17. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Ahmad M; Rees RC; Ali SA
Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
[TBL] [Abstract][Full Text] [Related]
18. Tumor counterattack: fact or fiction?
Igney FH; Krammer PH
Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
[TBL] [Abstract][Full Text] [Related]
19. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
20. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Yang D; Torres CM; Bardhan K; Zimmerman M; McGaha TL; Liu K
J Immunol; 2012 May; 188(9):4441-9. PubMed ID: 22461695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
